ATLANTIS Results: Lurbinectedin Plus Doxorubicin in SCLC ATLANTIS Results: Lurbinectedin Plus Doxorubicin in SCLC

Does improved safety and tolerability with lurbinectedin plus doxorubicin over standard of care in pretreated small cell lung cancer justify its use, despite seeing no survival benefit, ask experts.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news